| Chemical Properties | Back Directory | [Boiling point ]
540.5±50.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (199.88 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.12±0.29(Predicted) | [color ]
White to off-white | [InChI]
1S/C20H13F9N2O3/c1-17(33,16(32)31-13-3-2-10(8-30)15(7-13)20(27,28)29)9-34-14-5-11(18(21,22)23)4-12(6-14)19(24,25)26/h2-7,33H,9H2,1H3,(H,31,32) | [InChIKey]
VJIVKRQGSGBLFP-UHFFFAOYSA-N | [SMILES]
OC(C(NC1=CC(C(F)(F)F)=C(C#N)C=C1)=O)(C)COC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2 |
| Hazard Information | Back Directory | [Uses]
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity[1]. | [Biological Activity]
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity[1].
In LNCaPAR+ cells, SK33, demonstrates a significantly potent activity with IC50=0.2 μM. SK33 decreases cells entering S-phase in LNCaP cells. Treatment of LNCaP/BicR cells with increasing concentrations of SK33 for 96 hours results in a dose-dependent response and an inhibition of cell growth, with IC50 of approximately 5 μM for SK33[1].
SK33 (50 mg/kg; s.c.; 24 hours) inhibits AR transcriptional activity[1]. | [in vivo]
SK33 (50 mg/kg; s.c.; 24 hours) inhibits AR transcriptional activity[1]. | Animal Model: | ARE-Luc mice[1] | | Dosage: | 50 mg/kg | | Administration: | Subcutaneously; 24 hours | | Result: | Inhibited AR transcriptional activity. |
| [storage]
4°C, protect from light | [References]
[1]. Dart DA, et al. Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo.Mol Cancer Ther. 2018 Sep;17(9):1846-1858. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|